Kybernin P (Antithrombin Iii)

Kybernin P is used in the anticoagulation pathway to address antithrombin deficiency and related heparin‑resistance conditions.

• Hereditary antithrombin deficiency: supplementation restores antithrombin activity to reduce bleeding risk.
• Heparin resistance: provides antithrombin to enhance heparin efficacy during anticoagulant therapy.
• Cardiopulmonary bypass surgery: maintains adequate antithrombin levels to prevent intra‑operative clot formation.

• Antithrombin III is a serine protease inhibitor that binds to and inactivates thrombin (factor IIa) and factor Xa, as well as other coagulation enzymes. When administered intravenously, the concentrate raises plasma antithrombin concentrations, thereby potentiating the anticoagulant effect of heparin and directly limiting clot propagation. The increased antithrombin binds heparin via a specific pentasaccharide sequence, accelerating the inhibition of target proteases and restoring the balance between pro‑coagulant and anti‑coagulant forces in the circulation.

Kybernin P may be associated with infusion‑related adverse reactions and, rarely, severe systemic events.

Common Side Effects

• Fever: transient elevation of body temperature during or after infusion.
• Chills: shivering or feeling cold shortly after administration.
• Hypotension: mild drop in blood pressure that usually resolves with monitoring.
• Nausea: occasional upset stomach or feeling of queasiness.
• Headache: mild to moderate head pain during treatment.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
• Thrombosis: unexpected clot formation despite antithrombin supplementation.
• Hemolysis: destruction of red blood cells leading to anemia.
• Disseminated intravascular coagulation (DIC): widespread activation of clotting cascade.
• Renal failure: acute kidney injury potentially linked to infusion.

Before using Kybernin P, clinicians should observe several safety measures to minimize risks.

• Monitor antithrombin activity: measure plasma levels before and during therapy.
• Assess bleeding risk: evaluate patient history for recent surgery or hemorrhagic disorders.
• Review heparin therapy: adjust heparin dose as antithrombin concentrate may enhance its effect.
• Use caution in renal impairment: consider dose adjustments in patients with reduced kidney function.
• Avoid in known hypersensitivity: discontinue if allergic reaction occurs.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin P can interact with other medicines that affect coagulation or immune response.

Major Interactions (Avoid)

• Concurrent use with other anticoagulants (e.g., direct thrombin inhibitors, factor Xa inhibitors): may markedly increase bleeding risk.
• High‑dose heparin combined with antithrombin concentrate: can cause over‑anticoagulation and hemorrhage.
• Fresh frozen plasma administered simultaneously: may lead to unpredictable antithrombin levels.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (aspirin, clopidogrel): increase risk of bleeding and require close monitoring.
• Fibrinolytic therapy (tPA): additive effect on clot dissolution may enhance hemorrhagic complications.
• Other plasma protein products (e.g., albumin): monitor for potential immunogenic reactions.